A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
Status:
Active, not recruiting
Trial end date:
2021-11-12
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of
ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary
objective of this study is to evaluate treatment effect over time in adult participants with
RRMS treated with ALKS 8700.